Alessia Pepe1, Giuseppe Rossi2, Anthony Bentley3, Maria Caterina Putti4, Ludovica Frizziero4, Domenico Giuseppe D'Ascola5, Liana Cuccia6, Anna Spasiano7, Aldo Filosa7, Vincenzo Caruso8, Aishah Hanif3, Antonella Meloni9. 1. Magnetic Resonance Imaging Unit, Fondazione G. Monasterio CNR-Regione Toscana, Area della Ricerca S. Cataldo, Via Moruzzi, 56124, Pisa, Italy. alessia.pepe@ftgm.it. 2. Epidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy. 3. Decision Resources Group Abacus, Bicester, Oxfordshire, UK. 4. Dipartimento di Pediatria, Clinica di Emato-Oncologia Pediatrica, Università di Padova/Azienda Ospedaliera, Padua, Italy. 5. U.O. Microcitemie, A.O. "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy. 6. U.O.C. Ematologia con Talassemia, ARNAS Ospedale Civico, Palermo, Italy. 7. U.O.S.D. Centro per le Microcitemie, AORN Cardarelli, Naples, Italy. 8. U.O.D. Talassemia, ARNAS "Garibaldi", Catania, Italy. 9. Magnetic Resonance Imaging Unit, Fondazione G. Monasterio CNR-Regione Toscana, Area della Ricerca S. Cataldo, Via Moruzzi, 56124, Pisa, Italy.
Abstract
PURPOSE: Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS: A Markov model was used over a time horizon of 5 years. Italian-specific cost data were combined with Italian efficacy data. Costs and quality-adjusted life years (QALYs) were calculated for each treatment, with cost-effectiveness expressed as cost per QALY. RESULTS: In all scenarios modelled, DFP was the dominant treatment strategy. Sensitivity analyses showed that DFP dominated the other treatments with a >99% likelihood of being cost-effective against DFX and DFO at a willingness to pay threshold of €20,000 per QALY. CONCLUSIONS: DFP was the dominant and most cost-effective treatment for managing chronic iron overload in TM patients. Its use can result in substantial cost savings for the Italian healthcare system.
PURPOSE:Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS: A Markov model was used over a time horizon of 5 years. Italian-specific cost data were combined with Italian efficacy data. Costs and quality-adjusted life years (QALYs) were calculated for each treatment, with cost-effectiveness expressed as cost per QALY. RESULTS: In all scenarios modelled, DFP was the dominant treatment strategy. Sensitivity analyses showed that DFP dominated the other treatments with a >99% likelihood of being cost-effective against DFX and DFO at a willingness to pay threshold of €20,000 per QALY. CONCLUSIONS:DFP was the dominant and most cost-effective treatment for managing chronic iron overload in TM patients. Its use can result in substantial cost savings for the Italian healthcare system.
Authors: Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan Journal: Blood Date: 2005-12-22 Impact factor: 22.113
Authors: Emanuele Angelucci; Giovanni Barosi; Clara Camaschella; Maria Domenica Cappellini; Mario Cazzola; Renzo Galanello; Monia Marchetti; Antonio Piga; Sante Tura Journal: Haematologica Date: 2008-04-15 Impact factor: 9.941
Authors: Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan Journal: Haematologica Date: 2004-10 Impact factor: 9.941
Authors: Luciana Scalone; Lorenzo G Mantovani; Marieke Krol; Diana Rofail; Simona Ravera; Maria Grazia Bisconte; Caterina Borgna-Pignatti; Zelia Borsellino; Paolo Cianciulli; Domenico Gallisai; Luciano Prossomariti; Ippazio Stefàno; Maria D Cappellini Journal: Curr Med Res Opin Date: 2008-05-27 Impact factor: 2.580